Radiation-induced skin injury caused by interventional radiology(IVR)is a deterministic effect. If exposure dose exceeds threshold dose, injuries may occur. It therefore is important to understand the maximum exposure dose in skin. The purpose of this study was to determine the maximum exposure dose and its dose distribution. Moreover, to analyze the factors from measuring the absorbed dose in the incoming radiation side, a film-type dosimeter was used. When the measured results were determined in terms of the clinical aspect, fluoroscopic time(total time)in procedure, it ranged from 3.3 to 64.0 minutes, and DSA images obtained ranged from 8 to 280 images. Absorbed dose ranged from 0.3 to 6.0 Gy, with an average dose of 3.2 Gy. It thus exceeded 2 or 3 Gy, which was the threshold dose of temporary erythematic or depilation in 10 of 14 cases. The maximum dose was 6.0 Gy for a procedure of percutaneous transhepatic obliteration. The maximum exposure dose can be determined objectively by using a film-type dosimeter. It was also possible to grasp the overall dose distribution visually.

Download full-text PDF

Source
http://dx.doi.org/10.6009/jjrt.63.586DOI Listing

Publication Analysis

Top Keywords

exposure dose
16
dose
13
maximum exposure
12
threshold dose
8
dose distribution
8
absorbed dose
8
film-type dosimeter
8
[examination patient
4
patient skin
4
skin dose
4

Similar Publications

Orchestrated changes in cell arrangements and cell-to-cell contacts are susceptible to cellular stressors during central nervous system development. Effects of mitochondrial complex I inhibition on cell-to-cell contacts have been studied in vascular and intestinal structures; however, its effects on developing neuronal cells are largely unknown. We investigated the effects of the classical mitochondrial stressor and complex I inhibitor, rotenone, on the architecture of neural rosettes-radially organized neuronal progenitor cells (NPCs)-differentiated from human-induced pluripotent stem cells.

View Article and Find Full Text PDF

The present opinion deals with the re-evaluation of pullulan (E 1204) when used as a food additive and with the new application on the extension of use to several food categories. Pullulan (E 1204) is obtained by fermentation of a food-grade hydrolysed starch with non-genetically modified ■■■■■. Based on the available information, the Panel considered that the manufacturing process of pullulan (E 1204) using this microorganism does not raise a safety concern.

View Article and Find Full Text PDF

This study aimed to synthesize cetuximab (CTX) conjugated hydroxyapatite zirconium (HApZr-CTX) as a nanocarrier for active delivery of photosensitizer and therapeutic radionuclide. The system enabled targeted radioenhancer in X-ray dynamic therapy and radioimmunotherapy for lung cancer. The results showed that HApZr-CTX had the main characteristics of hydroxyapatite crystal in X-ray powder diffraction (XRD), with particle size twice bigger, according to DLS-PSA and TEM measurements.

View Article and Find Full Text PDF

Demonstration of virtual imaging trial applications for optimization and education of dento-maxillofacial CBCT imaging.

Med Phys

March 2025

KU Leuven, Department of Imaging and Pathology, Division of Medical Physics & Quality Assessment, Leuven, Belgium.

Background: A number of studies have suggested that there is a need for improved understanding of dento-maxillofacial cone beam computed tomography (CBCT) technology, and to establish optimized imaging protocols. While several ex vivo/in vitro studies, along with a few in vivo studies, have addressed this topic, virtual imaging trials could form a powerful alternative but have not yet been introduced within the field of dento-maxillofacial imaging.

Purpose: To introduce and illustrate the potential of utilizing a virtual imaging trial (VIT) platform for dento-maxillofacial CBCT imaging through a number of case studies.

View Article and Find Full Text PDF

This two-sequence, three-period study (NCT04645940) was designed to evaluate the effect of food and concomitant rabeprazole, a proton pump inhibitor, on the pharmacokinetics (PK) and safety of fruquintinib and its metabolite M11 after a single oral dose of fruquintinib 5 mg in healthy subjects. In the food effect treatment periods, 14 subjects were randomized in a 1:1 ratio utilizing a two-sequence (fed/fasted vs. fasted/fed), two-period, cross-over design.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!